DFMO-AMXT 1501 Co-crystal Dosage Form
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer involving the polyamine metabolic pathway, specifically combination drug therapies targeting the same biological pathway, are limited, and there is a need for optimized dosage forms that enhance bioavailability, stability, and patient compliance, particularly for AMXT 1501 and difluoromethylornithine (DFMO), which are currently administered separately.
Innovation Solution
A combination dosage form comprising DFMO and AMXT 1501, or their ionic forms, in a solid crystalline form, which enhances bioavailability, tissue targeting, and pharmacokinetic activity, and improves patient compliance and production feasibility by forming a stable co-crystal with increased melting points.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AMXT 1501 and DFMO are administered separately as individual dosage forms, then each drug can be optimized for its specific pharmacokinetic properties, but patient compliance deteriorates due to increased pill burden and complex dosing schedules
Solution Approach 1:
The patent combines two separate drugs (AMXT 1501 and DFMO) into a single co-crystal dosage form. This merging approach maintains the distinct pharmacokinetic properties of each drug while reducing the pill burden from two separate pills to one unified dosage form, thereby improving patient compliance without sacrificing therapeutic efficacy
2Ease of operation
If AMXT 1501 and DFMO are combined into a single dosage form, then patient compliance and pill burden are improved, but manufacturing complexity increases due to the need to form stable co-crystals with controlled ratios
Solution Approach 1:
The patent creates a co-crystal composite material consisting of AMXT 1501 and DFMO in a defined stoichiometric ratio (e.g., 1:1, 1:2, or 2:1). This composite approach allows both drugs to be integrated at the molecular level within a single crystal lattice, ensuring stable combination and precise dosing ratios while simplifying manufacturing compared to physical mixtures
3Stability of the object's composition
If a co-crystal form is formed to combine AMXT 1501 and DFMO, then stability and bioavailability are enhanced, but the melting point increases which may affect processing
Solution Approach 1:
The patent utilizes the characteristic parameter change that occurs during co-crystal formation, where the melting point of the combined structure is higher than the individual components. This parameter change is accepted and leveraged to achieve enhanced stability and bioavailability, with processing conditions adjusted to accommodate the higher melting point of the co-crystal structure
4Adaptability or versatility
If separate dosage forms are used for AMXT 1501 and DFMO, then dosing flexibility is maintained, but dosing consistency and ratio control deteriorate
Solution Approach 1:
By merging AMXT 1501 and DFMO into a single co-crystal dosage form with a defined stoichiometric ratio, the patent ensures that each unit of the medication contains precise, consistent amounts of both drugs. This eliminates variability in dosing ratios that can occur with separate administration, while the co-crystal structure itself provides the flexibility needed for different therapeutic regimens
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination dosage form improves bioavailability, enhances tumor targeting, and increases stability, leading to improved therapeutic efficacy and reduced pill burden, while maintaining sustained drug release and stability.
Implementation Method 1
ion-pairing of AMXT 1501 with DFMO may enhance drug bioavailability, tissue and/or tumor targeting and/or pharmacokinetic activity against tumors
Implementation Method 2
the combinations and solid forms provided herein are expected to provide one or more of the following advantages: (i) ion-pairing of AMXT 1501 with DFMO may enhance drug bioavailability
Implementation Method 3
The AMXT 1501-DFMO solid forms described herein have greatly increased melting point properties in comparison to their individual components
Data Source
AI summary
Provided herein are combinations comprising difluoromethylornithine (DFMO), or an ionic form thereof, and a compound of the following structural formula:or a protonated form thereof, wherein values for the variables (e.g., a, b, c, d, e, n, R1, R2, X) are described herein. The combinations can provide combination drug therapy in a single pharmaceutical dosage form, and be used, for example, for the treatment of cancer.